ॲक्युटास केमिकल्स शेअर किंमत

Pharmaceuticals company Acutaas Chemicals announced Q4FY26 & FY26 results Q4FY26 Consolidated Financial Highlights: Total Income: Rs 44,386.15 lakh in Q4FY26, compared to Rs 39,788.25 lakh in Q3FY26 (up 11.56% QoQ) and Rs 31,426.25 lakh in Q4FY25 (up 41.24% YoY). Revenue from Operations: Rs 43,275.05 lakh in Q4FY26, up from Rs 39,318.33 lakh in Q3FY26 (up 10.06% QoQ) and Rs 30,848.34 lakh in Q4FY25 (up 40.28% YoY). Profit Before Tax (PBT): Rs 18,380.17 lakh in Q4FY26, showing a growth of 27.05% QoQ from Rs 14,466.85 lakh and 121.89% YoY from Rs 8,283.44 lakh. Net Profit (PAT): Rs 13,428.37 lakh in Q4FY26, compared to Rs 10,621.92 lakh in Q3FY26 (up 26.42% QoQ) and Rs 6,271.61 lakh in Q4FY25 (up 114.11% YoY). FY26 Consolidated Financial Highlights: Total Income: Rs 1,38,095.20 lakh in FY26, compared to Rs 1,02,380.49 lakh in FY25, representing a YoY growth of 34.88%. Revenue from Operations: Rs 1,33,936.68 lakh in FY26, compared to Rs 1,00,687.55 lakh in FY25 (up 33.02% YoY). Profit Before Tax (PBT): Rs 48,272.57 lakh in FY26, marking a YoY growth of 123.32% from Rs 21,616.30 lakh in FY25. Net Profit (PAT): Rs 35,636.93 lakh in FY26, up from Rs 16,041.77 lakh in FY25 (up 122.15% YoY). Q4FY26 Standalone Financial Highlights: Total Income: Rs 43,631.82 lakh in Q4FY26, up from Rs 39,719.84 lakh in Q3FY26 (up 9.85% QoQ) and Rs 30,985.56 lakh in Q4FY25 (up 40.81% YoY). Revenue from Operations: Rs 42,177.23 lakh in Q4FY26, compared to Rs 39,085.56 lakh in Q3FY26 (up 7.91% QoQ) and Rs 30,416.14 lakh in Q4FY25 (up 38.67% YoY). Net Profit (PAT): Rs 13,707.12 lakh in Q4FY26, showing a growth of 22.86% QoQ from Rs 11,156.55 lakh and 118.11% YoY from Rs 6,284.68 lakh. FY26 Standalone Financial Highlights: Total Income: Rs 1,36,967.05 lakh in FY26, up 35.86% YoY from Rs 1,00,817.02 lakh in FY25. Revenue from Operations: Rs 1,32,379.22 lakh in FY26, compared to Rs 98,983.46 lakh in FY25 (up 33.74% YoY). Net Profit (PAT): Rs 36,617.45 lakh in FY26, compared to Rs 15,954.62 lakh in FY25 (up 129.51% YoY). Business Highlights Segment-wise Performance: The company operates in a Single Segment only. As per verbatim from the notes: "As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments." Dividend: The Board of Directors recommended a final dividend of Rs 2.5 per share (50%) on equity shares of face value of Rs 5 each for the FY 2025-26. Material Subsidiary: Based on latest audited consolidated financial statements, Indichem INC has met prescribed thresholds and is identified as a Material Subsidiary of the company. Joint Venture Investment: Acutaas Advance Material Limited (AAML), a wholly-owned subsidiary, entered into a joint venture with J & Materials Co. Ltd. (South Korea). AAML has made an investment of approximately Rs 190.52 crore in Indichem Inc. to acquire a 75% equity stake. Share Capital Change: During FY 2024-25, the company approved a sub-division of each equity share of face value of Rs 10 into two equity shares of face value of Rs 5 each. The record date for the split was April 25, 2025. Labour Code Assessment: The company assessed the impact of the new four Labour Codes. Verbatim from standalone notes: "the Company has assessed the impact of these changes and no material impact has been noticed under employee benefit expenses in the standalone audited financial results for the quarter | year ended on March 31, 2026." Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals, said: “I am pleased to report a strong close to FY26, with Q4 revenue from operations reaching Rs 4,328 million — up 40.3% YoY — and our highest ever PAT margin of 31.0%. Our strategy is clear: build a diversified chemicals business across three high-growth verticals — Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. By scaling these in parallel, we are de-risking our revenue base while creating multiple independent engines of compounding, long-term growth. We enter FY27 from a position of strength. I am confident of delivering 25% revenue growth in FY27.” Result PDF

• ट्रेंडलाईन
• 1 महिना 1 आठवड्यापूर्वी

Q3FY26 परफॉर्मन्स आणि आऊटलूकवर अक्टास केमिकल्स मॅनेजमेंट आणि ॲनालिस्टसह कॉन्फरन्स कॉल. पूर्ण कमाईची ट्रान्सक्रिप्ट ऐका.

• ट्रेंडलाईन
• 4 महिने 2 आठवड्यांपूर्वी

फार्मास्युटिकल्स कंपनी अक्टास केमिकल्सने Q3FY26 परिणामांची घोषणा केली Q3FY26 साठी ऑपरेशन्समधून महसूल 43.0% YoY ने वाढून ₹ 3,932 दशलक्ष झाला. तिमाहीसाठी एकूण मार्जिन 57.0% पर्यंत सुधारले, 1,073 bps YoY पर्यंत वाढ. तिमाहीसाठी EBITDA ₹1,507 दशलक्ष, 119.4% YoY वाढ. Q3FY25 मधील 25.0% च्या तुलनेत तिमाहीसाठी EBITDA मार्जिन 38.3% होता. तिमाहीसाठी पीएटी ₹1,062 दशलक्ष होता, Q3FY25 मध्ये ₹454 दशलक्षच्या पीएटीच्या तुलनेत 133.7% वाढ. तिमाहीसाठी पीएटी मार्जिन 27.0, % वाढीस 1,049 बीपीएस YoY. अकुटास केमिकल्सचे कार्यकारी अध्यक्ष आणि व्यवस्थापकीय संचालक नरेश पटेल म्हणाले: "बॅटरी रसायने आणि सेमीकंडक्टर रसायने व्हर्टिकल्स स्केलिंग करून आमच्या बिझनेस फाऊंडेशनला मजबूत करण्यासह सीएमओ/सीडीएमओ संधी जोडून आम्ही आमच्या मुख्य फार्मास्युटिकल मध्यवर्ती व्यवसायाला बळकट करणे सुरू ठेवतो. हे व्यवसाय, जे सध्या ॲक्टिव्ह कॅपिटल इन्व्हेस्टमेंट अंतर्गत आहेत, स्केलच्या दिशेने सतत प्रगती करीत आहेत. पुढील तीन वर्षांमध्ये, आम्ही प्रत्येक व्हर्टिकल स्वतंत्र, स्वयं-शाश्वत वाढीचे इंजिन म्हणून काम करण्याची अपेक्षा करतो, जे आमच्या एकूण टॉपलाईनमध्ये अर्थपूर्ण योगदान देते. मला हे सांगताना आनंद होत आहे की आम्ही आमच्या CDMO बिझनेसच्या निरंतर रॅम्प-अपद्वारे प्रेरित Q3 मध्ये मजबूत वाढीची गती टिकवून ठेवली आहे. आम्ही आर्थिक वर्षाच्या शेवटी प्रगती करत असताना, निरोगी ऑर्डर बुक आणि सुधारित दृश्यमानतेद्वारे समर्थित, आम्ही आमच्या महसूल वाढीच्या मार्गदर्शनात 25% पासून अंदाजे 30% पर्यंत सुधारणा करीत आहोत." परिणाम पीडीएफ

• ट्रेंडलाईन
• 4 महिने 2 आठवड्यांपूर्वी